Table 1.
Clinicopathological characteristics of breast cancer patients who underwent surgery and additional treatment
| Variables | n=1148 | |
|---|---|---|
| Age (years), mean±SD | 50.1±10.4 | |
|
| ||
| Body mass index (kg/m2), mean±SD | 23.6±3.3 | |
|
| ||
| History of bilateral breast cancer, n (%) | 24 (2.1) | |
|
| ||
| Hospital stay (days), mean±SD | 12.4±4.6 | |
|
| ||
| Clinical tumor size (cm), mean±SD | 2.3±1.5 | |
|
| ||
| Pathological tumor size (cm), mean±SD | 1.8±1.1 | |
|
| ||
| Types of tumor, n (%) | Invasive ductal carcinoma | 1053 (91.7) |
| Invasive lobular carcinoma | 38 (3.3) | |
| Mucinous carcinoma | 27 (2.4) | |
| Others | 30 (2.6) | |
|
| ||
| Histological grade, n (%) | 1 | 269 (23.4) |
| 2 | 597 (52.0) | |
| 3 | 282 (24.6) | |
|
| ||
| Pathological stage, n (%) | IA | 565 (49.2) |
| IB | 2 (0.2) | |
| IIA | 348 (30.3) | |
| IIB | 132 (11.5) | |
| IIIA | 69 (6.0) | |
| IIIB | 3 (0.3) | |
| IIIC | 29 (2.5) | |
|
| ||
| Estrogen receptor positive, n (%) | 798 (69.5) | |
|
| ||
| Progesterone receptor positive, n (%) | 690 (60.1) | |
|
| ||
| c-erbB2 gene positive, n (%) | 221 (19.3) | |
|
| ||
| Triple-negative breast cancer, n (%) | 86 (7.5) | |
|
| ||
| Type of breast surgery, n (%) | Breast conserving surgery | 636 (55.4) |
| Mastectomy | 512 (44.6) | |
|
| ||
| Type of axillary surgery, n (%) | Sentinel lymph node biopsy | 807 (70.3) |
| Axillary lymph node dissection | 341 (29.7) | |
|
| ||
| Neoadjuvant chemotherapy, n (%) | 104 (9.1) | |
|
| ||
| Adjuvant chemotherapy, n (%) | 695 (60.5) | |
|
| ||
| Adjuvant radiotherapy, n (%) | 676 (58.9) | |
|
| ||
| Adjuvant hormonal therapy, n (%) | 810 (70.6) | |
SD, standard deviation.